Bulletin
Investor Alert

New York Markets Open in:

Coronavirus Update Archives | Email alerts

Jan. 28, 2022, 12:44 p.m. EST

World hits milestone of 10 billion COVID vaccine doses administered, but less than 10% of people in low-income countries have had a first jab

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    Novavax Inc. (NVAX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

The world reached a COVID-19 vaccination milestone Friday of 10 billion doses administered globally, according to Our World in Data, but wealthier countries account for the vast majority, while poorer ones have been left behind.

Only 9.8% of people in low-income countries have received a first vaccine dose, according to the research company, while in wealthy countries many have had three doses, and some, such as Israel, are starting to offer a fourth.

Researchers at Duke University have estimated that the world needed at least 11 billion doses to fully inoculate 70% of its population of about 7 billion, but vaccine equity has been a challenge from the get-go, despite repeated warnings from the World Health Organization that leaving major areas of the world unvaccinated would allow new variants to emerge, and those could prove resistant to vaccines.

The highly infectious omicron variant, which was detected in December and has gone on to become the leading variant in most places, is just such an example. Omicron has caused many breakthrough cases in people who are fully vaccinated and even had a booster dose, but those cases are usually mild or asymptomatic.

The majority of hospitalizations and deaths from omicron are in unvaccinated people, who remain at high risk of contracting it as it spreads rapidly through communities.

 “It will be key that people in all countries — not just in rich countries — receive the required protection,” the World in Data team wrote.

The WHO is targeting vaccinating 70% of the world’s population this year and has said reaching that goal would move the world out of the “acute phase” of the pandemic, the period in which it remains an international emergency.

See: 400 million free N95 masks are starting to hit pharmacies — here’s how to extend their use, and recycle them

WHO Director-General Tedros Adhanom Ghebreyesus said this week that could happen if countries pull together to get vaccines to those parts of the world that have not received them and bolster testing, sequencing and monitoring of new variants.

“If countries use all of these strategies and tools in a comprehensive way, we can end the acute phase of the pandemic this year — we can end COVID-19 as a global health emergency, and we can do it this year,” said Tedros,  in a statement.

The World in Data team is skeptical that will happen.

COVID cases and hospitalizations are declining in the U.S., according to a New York Times tracker, although deaths, which are a lagging indicator, are steadily climbing. The U.S. is averaging 2,530 deaths a day, the tracker shows, up 34% from two weeks ago.

New cases are down 27% at 589,225 on average a day, while hospitalizations are averaging 151,066, up 1% from two weeks ago.

Don’t miss: New Yorkers should take a COVID test if they’ve been near Sarah Palin this week, mayor’s spokesman says

Other COVID-19 news you should know about:

• Merck /zigman2/quotes/209956077/composite MRK -1.27% and partner Ridgeback Biotherapeutics said Friday that data from six preclinical studies of their pill molnupiravir showed “consistent antiviral activity” against the omicron variant of the coronavirus that causes COVID-19. The preclinical studies were conducted independently in Belgium, the Czech Republic, Germany, Poland, the Netherlands and the U.S. Molnupiravir is currently authorized for use in 10 countries, including the U.S., the U.K. and Japan.

• Novavax /zigman2/quotes/202614340/composite NVAX +6.09% will supply 5 million doses of its protein-based COVID-19 vaccine to Israel as part of an advance purchase agreement, with the Israeli Ministry of Health also taking an option to buy an additional 5 million doses. Novavax is currently conducting two Phase 3 trials of the vaccine involving about 30,000 participants in the U.S. and Mexico, as well as a trial involving about 15,000 people in the U.K. Data from both trials were published in the New England Journal of Medicine and showed high efficacy and safety. The vaccine has been granted conditional marketing authorization in the EU and an emergency-use listing by the World Health Organization. It is currently under review by other regulatory bodies.

See also:   Walmart, Costco and other big box stores in Canada begin enforcing vaccine mandates, and some shoppers aren’t buying it

• China locked down an area neighboring the capital Beijing this week following a handful of reported COVID cases but made no public announcements about the fresh restrictions with just a week until the Winter Olympics, AFP reported. About 1.2 million people in Xiong’an New Area — a new economic zone 100 kilometers southwest of Beijing — are no longer allowed to enter or leave their residential compounds, the news agency reported, citing local virus-control staff.

• Finland will ease COVID restrictions from Feb. 1, according to its health minister. The Nordic nation of 5.5 million has maintained some of the European Union’s lowest incidence rates throughout the pandemic, but infections have increased in recent weeks due to the omicron variant.

See now: U.S. consumer spending slumps after omicron outbreak

Here’s what the numbers say

The global tally of confirmed cases of COVID-19 rose above 366.9 million, and the death toll is now more than 5.63 million,  according to data aggregated by Johns Hopkins University.

The U.S. leads the world with 73.4 million cases and 878,472 fatalities.

The  Centers for Disease Control and Prevention’s vaccine tracker  is showing that 211 million people living in the U.S. are fully vaccinated, equal to 63.6% of the total population.

Some 86 million have received a booster, equal to 41% of the fully vaccinated.

/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 108.61
-1.40 -1.27%
Volume: 12.42M
June 7, 2023 4:03p
P/E Ratio
21.21
Dividend Yield
2.69%
Market Cap
$279.14 billion
Rev. per Employee
$827,391
loading...
/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 7.67
+0.44 +6.09%
Volume: 5.85M
June 7, 2023 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$623.99 million
Rev. per Employee
$682,155
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.